Fertility and sterility最新文献

英文中文

Elevated triglyceride glucose-body mass index increases risk of miscarriage in women undergoing in vitro fertilization and embryo transfer 甘油三酯-葡萄糖体重指数升高会增加体外受精和胚胎移植妇女流产的风险。

IF 7 1区医学 Q1 OBSTETRICS & GYNECOLOGY

Fertility and sterility

Pub Date : 2026-03-01 Epub Date: 2025-09-09 DOI: 10.1016/j.fertnstert.2025.09.001

Ziyi Song M.A. , Fang Fang M.D. , Zhenteng Liu M.D. , Rong Liang M.D. , Ye Pan M.D. , Wenjia Meng M.A. , Fanwei Meng B.S. , Shuyi Zhang M.D. , Lihong Pang M.D. , Hongchu Bao M.D. , Qun Lu M.D., Ph.D.

<div><h3>Objective</h3><div>To explore the effects of triglyceride glucose-body mass index (TyG-BMI) on pregnancy outcomes of in vitro fertilization and embryo transfer.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Subjects</h3><div>This study included clinical data from 17,365 patients across 3 reproductive medicine centers in People’s Republic of China, encompassing both fresh embryo transfer (ET) cycles and subsequent frozen-thawed embryo transfer (FET) cycles.</div></div><div><h3>Exposure</h3><div>The subjects were categorized into four groups according to the TyG-BMI quartiles measured before cycle initiation: Quartile 1 (Q1): <166.9, Quartile 2 (Q2): 166.9–188.8, Quartile 3 (Q3): 188.8–218.8, Quartile 4 (Q4): ≥218.8.</div></div><div><h3>Main Outcome Measures</h3><div>Primary outcome: cumulative live birth rate (CLBR). Secondary outcomes: biochemical pregnancy rate, clinical pregnancy rate, miscarriage rate, and live birth rate.</div></div><div><h3>Results</h3><div>A higher TyG-BMI was significantly associated with increased miscarriage rates (fresh ET cycles: Q4 vs. Q1: odds ratio [OR] = 1.41, 95% confidence interval [CI]: 1.09–1.83; FET cycles: Q2 vs. Q1: OR = 1.24, 95% CI: 1.06–1.45; Q3 vs. Q1: OR = 1.36, 95% CI: 1.17–1.60; Q4 vs. Q1: OR = 1.57, 95% CI: 1.34–1.84) in both fresh ET and FET cycles. Additionally, a higher TyG-BMI was associated with lower live birth rate (Q4 vs. Q1: OR = 0.88, 95% CI: 0.80–0.97) in FET cycles. In cumulative cycles, patients with a higher TyG-BMI exhibited a significantly lower CLBR (Q2 vs. Q1: OR = 0.90, 95% CI: 0.82–0.99; Q3 vs. Q1: OR = 0.87, 95% CI: 0.79–0.95; Q4 vs. Q1: OR = 0.78, 95% CI: 0.71–0.85). The linear negative correlation between the TyG-BMI and CLBR was further confirmed by the restricted cubic splines. Subgroup analyses based on age and ovarian reserve revealed that a high TyG-BMI had a more pronounced adverse impact on younger women (<35 y) and those with polycystic ovary syndrome or normal ovarian reserve. However, this association was not observed in older patients (≥35 y) or those with diminished ovarian reserve.</div></div><div><h3>Conclusion</h3><div>As TyG-BMI increased, the miscarriage rates in fresh ET and FET cycles increased, whereas live birth rates in FET cycles and CLBR declined. These findings suggest that TyG-BMI may serve as a practical marker for identifying patients at increased metabolic risk for adverse pregnancy outcomes before in vitro fertilization treatment.</div></div><div><div>El índice elevado de triglicéridos-glucosa y masa corporal aumenta el riesgo de aborto espontáneo en mujeres sometidas a fecundación in vitro y transferencia de embriones</div></div><div><h3>Objetivo</h3><div>Explorar los efectos del índice triglicéridos glucosa-índice de masa corporal (TyG-IMC) sobre los resultados del embarazo tras la fecundación in vitro y la transferencia de embriones.</div></div><div><h3>Diseño</h3><div>Estudio de cohorte retro

目的探讨甘油三酯-葡萄糖体重指数（TyG-BMI）对体外受精和胚胎移植（IVF-ET）妊娠结局的影响。设计回顾性队列研究。本研究纳入了来自中国三个生殖医学中心的17365例患者的临床数据，包括新鲜胚胎移植（ET）周期和随后的冻融胚胎移植（FET）周期。根据循环开始前测量的TyG-BMI四分位数将受试者分为四组：四分位数1 (Q1): < 166.9，四分位数2 (Q2): 166.9-188.8，四分位数3 (Q3): 188.8-218.8，四分位数4 (Q4):≥218.8。主要结局指标：累积活产率（CLBR）。第二项指标：生化妊娠率、临床妊娠率、流产率、活产率。结果较高的TyG-BMI与新鲜ET和FET周期流产率增加显著相关（新鲜ET周期：Q4 vs Q1: OR=1.41, 95%CI: 1.09-1.83， P=0.008； FET周期：Q2 vs Q1: OR=1.24, 95%CI: 1.06-1.45， P<0.001; Q3 vs Q1: OR=1.36, 95%CI: 1.17-1.60， P<0.001; Q4 vs Q1: OR=1.57, 95%CI: 1.34-1.84， P<0.001）。此外，在FET周期中，较高的TyG-BMI与较低的活产率相关（Q4 vs Q1: OR=0.88, 95%CI: 0.80-0.97， P=0.011）。在累积周期中，TyG-BMI较高的患者表现出明显较低的CLBR （Q2 vs Q1: OR=0.90, 95%CI: 0.82-0.99， P=0.025; Q3 vs Q1: OR=0.87, 95%CI: 0.79-0.95， P=0.003; Q4 vs Q1: OR=0.78, 95%CI: 0.71-0.85， P<0.001）。限制三次样条进一步证实了TyG-BMI与CLBR之间的线性负相关（p -非线性= 0.159，p总体< 0.001）。基于年龄和卵巢储备的亚组分析显示，高TyG-BMI对年轻女性（<35岁）、多囊卵巢综合征（PCOS）或卵巢储备正常的女性有更明显的不良影响。然而，在年龄较大（≥35岁）或卵巢储备功能减退（DOR）的患者中未观察到这种关联。结论随着TyG-BMI的升高，新鲜ET和FET周期流产率升高，FET周期活产率和累计活产率下降。这些发现表明，TyG-BMI可以作为一种实用的标记物，用于识别体外受精治疗前代谢风险增加的不良妊娠结局患者。

{"title":"Elevated triglyceride glucose-body mass index increases risk of miscarriage in women undergoing in vitro fertilization and embryo transfer","authors":"Ziyi Song M.A. , Fang Fang M.D. , Zhenteng Liu M.D. , Rong Liang M.D. , Ye Pan M.D. , Wenjia Meng M.A. , Fanwei Meng B.S. , Shuyi Zhang M.D. , Lihong Pang M.D. , Hongchu Bao M.D. , Qun Lu M.D., Ph.D.","doi":"10.1016/j.fertnstert.2025.09.001","DOIUrl":"10.1016/j.fertnstert.2025.09.001","url":null,"abstract":"<div><h3>Objective</h3><div>To explore the effects of triglyceride glucose-body mass index (TyG-BMI) on pregnancy outcomes of in vitro fertilization and embryo transfer.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Subjects</h3><div>This study included clinical data from 17,365 patients across 3 reproductive medicine centers in People’s Republic of China, encompassing both fresh embryo transfer (ET) cycles and subsequent frozen-thawed embryo transfer (FET) cycles.</div></div><div><h3>Exposure</h3><div>The subjects were categorized into four groups according to the TyG-BMI quartiles measured before cycle initiation: Quartile 1 (Q1): <166.9, Quartile 2 (Q2): 166.9–188.8, Quartile 3 (Q3): 188.8–218.8, Quartile 4 (Q4): ≥218.8.</div></div><div><h3>Main Outcome Measures</h3><div>Primary outcome: cumulative live birth rate (CLBR). Secondary outcomes: biochemical pregnancy rate, clinical pregnancy rate, miscarriage rate, and live birth rate.</div></div><div><h3>Results</h3><div>A higher TyG-BMI was significantly associated with increased miscarriage rates (fresh ET cycles: Q4 vs. Q1: odds ratio [OR] = 1.41, 95% confidence interval [CI]: 1.09–1.83; FET cycles: Q2 vs. Q1: OR = 1.24, 95% CI: 1.06–1.45; Q3 vs. Q1: OR = 1.36, 95% CI: 1.17–1.60; Q4 vs. Q1: OR = 1.57, 95% CI: 1.34–1.84) in both fresh ET and FET cycles. Additionally, a higher TyG-BMI was associated with lower live birth rate (Q4 vs. Q1: OR = 0.88, 95% CI: 0.80–0.97) in FET cycles. In cumulative cycles, patients with a higher TyG-BMI exhibited a significantly lower CLBR (Q2 vs. Q1: OR = 0.90, 95% CI: 0.82–0.99; Q3 vs. Q1: OR = 0.87, 95% CI: 0.79–0.95; Q4 vs. Q1: OR = 0.78, 95% CI: 0.71–0.85). The linear negative correlation between the TyG-BMI and CLBR was further confirmed by the restricted cubic splines. Subgroup analyses based on age and ovarian reserve revealed that a high TyG-BMI had a more pronounced adverse impact on younger women (<35 y) and those with polycystic ovary syndrome or normal ovarian reserve. However, this association was not observed in older patients (≥35 y) or those with diminished ovarian reserve.</div></div><div><h3>Conclusion</h3><div>As TyG-BMI increased, the miscarriage rates in fresh ET and FET cycles increased, whereas live birth rates in FET cycles and CLBR declined. These findings suggest that TyG-BMI may serve as a practical marker for identifying patients at increased metabolic risk for adverse pregnancy outcomes before in vitro fertilization treatment.</div></div><div><div>El índice elevado de triglicéridos-glucosa y masa corporal aumenta el riesgo de aborto espontáneo en mujeres sometidas a fecundación in vitro y transferencia de embriones</div></div><div><h3>Objetivo</h3><div>Explorar los efectos del índice triglicéridos glucosa-índice de masa corporal (TyG-IMC) sobre los resultados del embarazo tras la fecundación in vitro y la transferencia de embriones.</div></div><div><h3>Diseño</h3><div>Estudio de cohorte retro","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"125 3","pages":"Pages 466-476"},"PeriodicalIF":7.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145035550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low return to care rates among women who underwent oocyte cryopreservation for oncological indications: a Society for Assisted Reproductive Technology data analysis 因肿瘤适应症而接受卵母细胞冷冻保存的妇女回护率低：一项SART数据分析。

IF 7 1区医学 Q1 OBSTETRICS & GYNECOLOGY

Fertility and sterility

Pub Date : 2026-03-01 Epub Date: 2025-10-10 DOI: 10.1016/j.fertnstert.2025.09.038

Alison J. Meyers B.A. , Yuval Fouks M.D., M.P.H. , Pietro Bortoletto M.D., M.Sc. , Alan S. Penzias M.D. , Denny Sakkas Ph.D. , Denis A. Vaughan M.D.

引用次数: 0

Compassionate transfer: patient requests for embryo transfer for nonreproductive purposes: an Ethics Committee opinion 同情移植：非生殖目的的患者胚胎移植请求：伦理委员会意见。

IF 7 1区医学 Q1 OBSTETRICS & GYNECOLOGY

Fertility and sterility

Pub Date : 2026-03-01 Epub Date: 2026-03-03 DOI: 10.1016/j.fertnstert.2025.12.013

Compassionate transfer refers to patient requests to transfer embryos into their bodies in a location or at a time when pregnancy is not expected to occur and reflects their personal preferences and values. It is ethical for physicians to honor or decline such requests if they do so in a nondiscriminatory and unbiased manner. This document replaces the document of the same name, last published in 2020 (Fertil Steril 2020; 113:62–5)

Transferencia compasiva: solicitudes por parte de pacientes de transferencias embrionarias con fines no reproductivos: una opinión del Comité de Ética

La transferencia compasiva se refiere a solicitudes por parte de pacientes de transferir embriones a partes de su cuerpo o en momentos en los que no se espera que pueda ocurrir un embarazo y refleja sus preferencias y valores personales. Es ético que los médicos honren o rechacen dichas solicitudes si lo hacen de manera no discriminatoria y no sesgada. Este documento reemplaza al documento del mismo nombre, publicado por última vez en 2020 (Fertil Steril 2020; 113:62–5).

同情移植指的是患者要求在不可能怀孕的地点或时间将胚胎移植到自己体内，这反映了他们的个人偏好和价值观。如果医生以非歧视和公正的方式尊重或拒绝这些请求，这是合乎道德的。本文档取代上次发布于2020年的同名文档（Fertil Steril 2020; 113:62-5）。

引用次数: 0

Association between serum estradiol level decline in the days preceding ovulatory trigger and assisted reproductive technology outcomes. 排卵触发前几天血清雌二醇水平下降与辅助生殖技术结果之间的关系。

IF 6.7 1区医学 Q1 OBSTETRICS & GYNECOLOGY

Fertility and sterility

Pub Date : 2026-02-28 DOI: 10.1016/j.fertnstert.2026.02.030

Peter Lindner,Kerry Flannagan,Charlene Echague,Amalia Namath,Jerry Wang,Jeanne E O'Brien,Phillip Romanski

OBJECTIVETo study whether a decline in serum estradiol level in the days leading up to the ovulatory trigger in GnRH antagonist ovarian stimulation cycles impacts cycle outcomes.DESIGNRetrospective cohort study SUBJECTS: Patients undergoing autologous retrieval cycles using a GnRH antagonist protocol between 2010-2021 at a multicenter infertility practice network in the United States. Patients were excluded if an estradiol level wasn't measured on the four days prior to the ovulatory trigger or if they had conventional insemination.EXPOSUREPatients with a documented decrease of at least 1 pg/mL in serum estradiol on any of the four days prior to ovulatory trigger. The referent group experienced a consistent rise in serum estradiol each day before trigger.MAIN OUTCOME MEASURESThe primary outcome was the number of usable blastocysts, defined as the sum of blastocysts used for fresh transfer (if any) and the remaining cryopreserved blastocysts. Secondary outcomes included oocyte maturity, fertilization, ≥1 usable blastocyst, positive hCG, biochemical pregnancy, spontaneous abortion, clinical pregnancy, and live birth.RESULTS6,945 cycles met inclusion criteria. Among this cohort, 5,653 demonstrated a consistent rise in serum estradiol, 1,103 cycles experienced one drop, and 189 cycles experienced 2-4 drops in estradiol during the four days preceding ovulatory trigger. After adjusting for AMH and female age, there was no difference in the average number of usable blastocysts between the referent group (4.9± 4.0) and cycles with a single drop in estradiol (5.2± 4.8) (mean ratio 1.04, 95%CI 0.97-1.10) and those with 2-4 drops in estradiol (mean ratio 0.98, 95%CI 0.85-1.14). There were no statistical differences in any of the secondary outcomes including live birth. Live birth was observed at 41.1% for the consistent rise group, 36.8% for the one drop group (RR 0.91, 95% CI 0.81-1.02), and 42.1% for the 2-4 drops group (RR 0.98, 95% CI 0.74-1.28).CONCLUSIONS/RELEVANCEThe findings underscore that a decline in serum estradiol in the four days prior to ovulatory trigger does not affect to compromised oocyte quality. Patients with an estradiol decline that proceeded oocyte retrieval had comparable outcomes to patients in which a continued estradiol increase occurs.

目的研究GnRH拮抗剂卵巢刺激周期排卵触发前几天血清雌二醇水平下降是否影响周期结局。设计：回顾性队列研究对象：2010-2021年在美国多中心不孕实践网络中使用GnRH拮抗剂方案进行自体回收周期的患者。如果患者在排卵触发前四天没有测量雌二醇水平，或者如果他们进行了传统的人工授精，则排除在外。暴露：在排卵触发前4天的任何一天，血清雌二醇下降至少1 pg/mL的患者。参照组在触发前每天的血清雌二醇持续上升。主要结局指标主要结局是可用囊胚的数量，定义为用于新鲜移植的囊胚（如果有的话）和剩余冷冻保存的囊胚的总数。次要结局包括卵母细胞成熟、受精、≥1个可用囊胚、hCG阳性、生化妊娠、自然流产、临床妊娠和活产。结果6945个周期符合纳入标准。在该队列中，5653例患者血清雌二醇持续升高，1103例患者出现1次下降，189例患者在排卵触发前4天出现2-4次下降。经AMH和女性年龄校正后，参考组（4.9±4.0）、雌二醇单次下降周期（5.2±4.8）（平均比值1.04,95%CI 0.97-1.10）和雌二醇2-4次下降周期（平均比值0.98,95%CI 0.85-1.14）可用囊胚数的平均值无差异。包括活产在内的任何次要结局均无统计学差异。连续上升组的活产率为41.1%，一次下降组为36.8% (RR 0.91, 95% CI 0.81-1.02)， 2-4次下降组为42.1% （RR 0.98, 95% CI 0.74-1.28）。结论/相关性研究结果强调，排卵触发前4天血清雌二醇的下降不会影响受损的卵母细胞质量。雌二醇水平下降的患者进行卵母细胞回收的结果与雌二醇水平持续升高的患者相当。

{"title":"Association between serum estradiol level decline in the days preceding ovulatory trigger and assisted reproductive technology outcomes.","authors":"Peter Lindner,Kerry Flannagan,Charlene Echague,Amalia Namath,Jerry Wang,Jeanne E O'Brien,Phillip Romanski","doi":"10.1016/j.fertnstert.2026.02.030","DOIUrl":"https://doi.org/10.1016/j.fertnstert.2026.02.030","url":null,"abstract":"OBJECTIVETo study whether a decline in serum estradiol level in the days leading up to the ovulatory trigger in GnRH antagonist ovarian stimulation cycles impacts cycle outcomes.DESIGNRetrospective cohort study SUBJECTS: Patients undergoing autologous retrieval cycles using a GnRH antagonist protocol between 2010-2021 at a multicenter infertility practice network in the United States. Patients were excluded if an estradiol level wasn't measured on the four days prior to the ovulatory trigger or if they had conventional insemination.EXPOSUREPatients with a documented decrease of at least 1 pg/mL in serum estradiol on any of the four days prior to ovulatory trigger. The referent group experienced a consistent rise in serum estradiol each day before trigger.MAIN OUTCOME MEASURESThe primary outcome was the number of usable blastocysts, defined as the sum of blastocysts used for fresh transfer (if any) and the remaining cryopreserved blastocysts. Secondary outcomes included oocyte maturity, fertilization, ≥1 usable blastocyst, positive hCG, biochemical pregnancy, spontaneous abortion, clinical pregnancy, and live birth.RESULTS6,945 cycles met inclusion criteria. Among this cohort, 5,653 demonstrated a consistent rise in serum estradiol, 1,103 cycles experienced one drop, and 189 cycles experienced 2-4 drops in estradiol during the four days preceding ovulatory trigger. After adjusting for AMH and female age, there was no difference in the average number of usable blastocysts between the referent group (4.9± 4.0) and cycles with a single drop in estradiol (5.2± 4.8) (mean ratio 1.04, 95%CI 0.97-1.10) and those with 2-4 drops in estradiol (mean ratio 0.98, 95%CI 0.85-1.14). There were no statistical differences in any of the secondary outcomes including live birth. Live birth was observed at 41.1% for the consistent rise group, 36.8% for the one drop group (RR 0.91, 95% CI 0.81-1.02), and 42.1% for the 2-4 drops group (RR 0.98, 95% CI 0.74-1.28).CONCLUSIONS/RELEVANCEThe findings underscore that a decline in serum estradiol in the four days prior to ovulatory trigger does not affect to compromised oocyte quality. Patients with an estradiol decline that proceeded oocyte retrieval had comparable outcomes to patients in which a continued estradiol increase occurs.","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"99 1","pages":""},"PeriodicalIF":6.7,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147329195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to 'Coping with fertility decline: tackling the new reproductive challenge' [Fertil Steril 2026; 125:183-6]. “应对生育率下降：应对新的生殖挑战”的勘误表[Fertil Steril 2026；125:183-6]。

IF 7 1区医学 Q1 OBSTETRICS & GYNECOLOGY

Fertility and sterility

Pub Date : 2026-02-27 DOI: 10.1016/j.fertnstert.2026.02.013

引用次数: 0

DON'T LET HYPE OUTRUN EVIDENCE: WHY PGT-P SHOULDN'T BE RUSHED INTO CLINICS. 不要让炒作超过证据：为什么pgt-p不应该匆忙进入诊所。

IF 7 1区医学 Q1 OBSTETRICS & GYNECOLOGY

Fertility and sterility

Pub Date : 2026-02-27 DOI: 10.1016/j.fertnstert.2026.02.029

Anuja Dokras, Clarisa Gracia

引用次数: 0

Racial/ethnic variation in ovarian responsiveness and live birth after in vitro fertilization. 体外受精后卵巢反应性和活产的种族差异。

IF 7 1区医学 Q1 OBSTETRICS & GYNECOLOGY

Fertility and sterility

Pub Date : 2026-02-26 DOI: 10.1016/j.fertnstert.2026.02.028

Iris T Lee, Nathanael Koelper, Monica Mainigi, Dara S Berger, Suneeta Senapati

Objective: To evaluate racial/ethnic variation in ovarian responsiveness to stimulation during in vitro fertilization (IVF); and to compare the association between ovarian responsiveness and live birth by race/ethnicity.

Design: Retrospective cohort study.

Subjects: Women who underwent ovarian stimulation for IVF between 2017 and 2019 as reported to the Society for Assisted Reproductive Technology Clinic Outcome Reporting System.

Exposure: Race/ethnicity (Asian, Black, Hispanic, Other/Mixed, White); and ovarian sensitivity index (OSI).

Main outcome measures: Ovarian sensitivity index (number of oocytes retrieved/total gonadotropin dose ×1,000) adjusting for age at retrieval, body mass index, reporting year, number of prior cycles, antimüllerian hormone, and infertility diagnosis; and cumulative live birth adjusting for the above confounders and stratified by race/ethnicity.

Results: A total of 246,132 retrieval cycles with race/ethnicity data were included: 46,939 (19.1%) among Asian patients, 17,013 (6.9%) among Black, 18,334 (7.4%) among Hispanic, 2,817 (1.1%) among Other/Mixed, and 161,029 (65.4%) among White. Adjusting for confounders, Black participants had a higher OSI compared with White participants (5.4, 95% confidence interval [CI] 5.1-5.5, vs. 5.1, 95% CI 5.1-5.1) and Asian participants had a lower OSI (4.8, 95% CI 4.1-4.8). Of the retrieval cycles, 68,107 resulted in fresh embryo transfers, and a total of 169,405 frozen embryo transfers were performed. Despite higher OSI, Black participants had lower cumulative live birth compared with White participants (45.5% vs. 60.8%). When stratifying by race/ethnicity, higher OSI was consistently associated with an increased odds of cumulative live birth (adjusted odds ratio [aOR] ranging from 1.23, 95% CI 1.01-1.48, for Other/Mixed to 1.49, 95% CI 1.41-1.53, for White), with no significant difference in the strength of association by race/ethnicity.

Conclusion: Higher ovarian responsiveness is associated with increased odds of cumulative live birth. However, despite higher ovarian responsiveness to stimulation, Black participants experience lower odds of cumulative live birth compared with White participants. This disparity in IVF outcomes likely arises from factors beyond differences in responsiveness to stimulation.

目的：1)评估体外受精（IVF）过程中卵巢对刺激反应性的种族/民族差异；2)按种族/民族比较卵巢反应性与活产之间的关系设计：回顾性队列研究对象：2017-2019年间接受体外受精卵巢刺激的女性，并向辅助生殖技术临床结果报告系统报告。暴露：1)种族/民族（亚洲人、黑人、西班牙人、其他/混血儿、白人）；2)卵巢敏感性指数（OSI）主要观察指标：1)OSI（取卵数/促性腺激素总剂量× 1000），根据取卵年龄、体重指数、报告年份、既往周期数、抗苗勒管激素和不孕症诊断进行调整；结果：共纳入246132个包含种族/族裔数据的检索周期：亚洲患者46939例（19.1%），黑人患者17013例（6.9%），西班牙裔患者18334例（7.4%），其他/混血患者2817例（1.1%），白人患者161029例（65.4%）。调整混杂因素后，黑人受试者的OSI高于白人受试者（5.4,95% CI 5.3-5.5, vs . 5.1, 95% CI 5.1-5.1）。结论：较高的卵巢反应性与累积活产的几率增加有关。然而，尽管卵巢对刺激的反应性更高，与白人参与者相比，黑人参与者的累积活产几率更低。体外受精结果的差异可能是由于对刺激的反应不同以外的因素造成的。

{"title":"Racial/ethnic variation in ovarian responsiveness and live birth after in vitro fertilization.","authors":"Iris T Lee, Nathanael Koelper, Monica Mainigi, Dara S Berger, Suneeta Senapati","doi":"10.1016/j.fertnstert.2026.02.028","DOIUrl":"10.1016/j.fertnstert.2026.02.028","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate racial/ethnic variation in ovarian responsiveness to stimulation during in vitro fertilization (IVF); and to compare the association between ovarian responsiveness and live birth by race/ethnicity.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Subjects: </strong>Women who underwent ovarian stimulation for IVF between 2017 and 2019 as reported to the Society for Assisted Reproductive Technology Clinic Outcome Reporting System.</p><p><strong>Exposure: </strong>Race/ethnicity (Asian, Black, Hispanic, Other/Mixed, White); and ovarian sensitivity index (OSI).</p><p><strong>Main outcome measures: </strong>Ovarian sensitivity index (number of oocytes retrieved/total gonadotropin dose ×1,000) adjusting for age at retrieval, body mass index, reporting year, number of prior cycles, antimüllerian hormone, and infertility diagnosis; and cumulative live birth adjusting for the above confounders and stratified by race/ethnicity.</p><p><strong>Results: </strong>A total of 246,132 retrieval cycles with race/ethnicity data were included: 46,939 (19.1%) among Asian patients, 17,013 (6.9%) among Black, 18,334 (7.4%) among Hispanic, 2,817 (1.1%) among Other/Mixed, and 161,029 (65.4%) among White. Adjusting for confounders, Black participants had a higher OSI compared with White participants (5.4, 95% confidence interval [CI] 5.1-5.5, vs. 5.1, 95% CI 5.1-5.1) and Asian participants had a lower OSI (4.8, 95% CI 4.1-4.8). Of the retrieval cycles, 68,107 resulted in fresh embryo transfers, and a total of 169,405 frozen embryo transfers were performed. Despite higher OSI, Black participants had lower cumulative live birth compared with White participants (45.5% vs. 60.8%). When stratifying by race/ethnicity, higher OSI was consistently associated with an increased odds of cumulative live birth (adjusted odds ratio [aOR] ranging from 1.23, 95% CI 1.01-1.48, for Other/Mixed to 1.49, 95% CI 1.41-1.53, for White), with no significant difference in the strength of association by race/ethnicity.</p><p><strong>Conclusion: </strong>Higher ovarian responsiveness is associated with increased odds of cumulative live birth. However, despite higher ovarian responsiveness to stimulation, Black participants experience lower odds of cumulative live birth compared with White participants. This disparity in IVF outcomes likely arises from factors beyond differences in responsiveness to stimulation.</p>","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":" ","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147321565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of antidepressants and assisted reproductive technology treatment outcomes: a Danish nationwide register-based cohort study. 使用抗抑郁药和辅助生殖技术治疗结果：一项丹麦全国登记队列研究。

IF 7 1区医学 Q1 OBSTETRICS & GYNECOLOGY

Fertility and sterility

Pub Date : 2026-02-25 DOI: 10.1016/j.fertnstert.2026.02.026

Line Riis Jølving, Trine Munk-Olsen, Ola Torseth, Jens Fedder, Bente Mertz Nørgård, Michael Due Larsen

Objective: To examine the association between antidepressants and clinical pregnancy and live birth after embryo transfer in women with mild to moderate depression.

Design: This register-based observational study comprised all Danish women undergoing assisted reproductive technology (ART) treatment from 2006 to 2019.

Subjects: A nationwide cohort of 44,542 women with 123,146 embryo transfers.

Exposure: The exposed cohorts were either women exposed to antidepressants at the time of embryo transfer (current users) or women who discontinued treatment before embryo transfer (recent users), reflecting mild to moderate depression. Women without a history of antidepressant use constituted the unexposed cohort.

Main outcome measures: We used a multilevel mixed-effects generalized linear model, accounting for multiple embryo transfers, to examine the chance of clinical pregnancy and live birth after ART treatment in women currently or recently treated with antidepressants, compared with women without antidepressants.

Results: A total of 1,057 women (median age 35 [interquartile range: 31-39]) were current users and had 2,154 embryo transfers, 1,580 women were recent users and had 2,780 transfers, and 42,861 women without use of antidepressants had 118,212 transfers. The relative risk (RR) of clinical pregnancy in women with current use was 0.97 (95% confidence interval [CI]: 0.90-1.04), and 0.94 (95% CI: 0.79-1.11) for live birth. The confounder-adjusted RR was 0.96 (95% CI: 0.87-1.03) for clinical pregnancy, and 0.96 (95% CI: 0.87-1.00) for live birth among current users. For recent users, the RRs of clinical pregnancy, and live birth were 0.94 (95% CI: 0.87-1.00), and 0.99 (95% CI: 0.85-1.14), respectively, and the adjusted RRs 0.94 (95% CI: 0.86-1.01) for clinical pregnancy and 1.04 (95% CI: 0.90-1.20) for live birth.

Conclusion: Based on nationwide data from more than a decade, we found that current or recent use of antidepressants at the time of embryo transfer was not associated with a decreased chance of clinical pregnancy or live birth. The findings suggest that for women treated with antidepressants, ART treatment is as successful as for women without.

目的：我们旨在研究抗抑郁药物与轻至中度抑郁症患者胚胎移植后临床妊娠和活产的关系。设计：这项基于登记的观察性研究包括2006年至2019年接受辅助生殖技术（ART）治疗的所有丹麦妇女。研究对象：全国44,542名妇女进行了123,146次胚胎移植。暴露：暴露队列要么是在胚胎移植时暴露于抗抑郁药的妇女（当前使用者），要么是在胚胎移植前停止治疗的妇女（最近使用者），反映轻度至中度抑郁症。没有抗抑郁药使用史的女性构成未暴露组。主要结局指标：我们使用了一个多水平混合效应广义线性模型，考虑了多个胚胎移植，来检查目前或最近接受抗抑郁药物治疗的妇女在ART治疗后临床妊娠和活产的机会，与未接受抗抑郁药物治疗的妇女相比。结果：共有1057名女性（中位年龄35岁[IQR: 31-39]）是目前的使用者，进行了2154次胚胎移植；1580名女性是最近的使用者，进行了2780次胚胎移植；42861名未使用抗抑郁药物的女性进行了118,212次胚胎移植。目前使用该药物的妇女临床妊娠的相对危险度（RR）为0.97 (95% CI: 0.90-1.04)，活产的相对危险度为0.94 （95% CI: 0.79-1.11）。临床妊娠的混杂校正RR为0.96 (95% CI: 0.87-1.03)，当前用户中活产的RR为0.96 （95% CI: 0.87-1.00）。对于近期使用者，临床妊娠和活产的RRs分别为0.94 （95% CI: 0.87-1.00）和0.99 (95% CI: 0.85-1.14)，临床妊娠的RRs为0.94 (95% CI: 0.86-1.01)，活产的RRs为1.04 （95% CI: 0.90-1.20）。结论：基于十多年来全国范围内的数据，我们发现目前或最近在胚胎移植时使用抗抑郁药与临床妊娠或活产机会的降低无关。研究结果表明，对于接受抗抑郁药物治疗的妇女，抗逆转录病毒治疗与未接受抗抑郁药物治疗的妇女一样成功。

{"title":"Use of antidepressants and assisted reproductive technology treatment outcomes: a Danish nationwide register-based cohort study.","authors":"Line Riis Jølving, Trine Munk-Olsen, Ola Torseth, Jens Fedder, Bente Mertz Nørgård, Michael Due Larsen","doi":"10.1016/j.fertnstert.2026.02.026","DOIUrl":"10.1016/j.fertnstert.2026.02.026","url":null,"abstract":"<p><strong>Objective: </strong>To examine the association between antidepressants and clinical pregnancy and live birth after embryo transfer in women with mild to moderate depression.</p><p><strong>Design: </strong>This register-based observational study comprised all Danish women undergoing assisted reproductive technology (ART) treatment from 2006 to 2019.</p><p><strong>Subjects: </strong>A nationwide cohort of 44,542 women with 123,146 embryo transfers.</p><p><strong>Exposure: </strong>The exposed cohorts were either women exposed to antidepressants at the time of embryo transfer (current users) or women who discontinued treatment before embryo transfer (recent users), reflecting mild to moderate depression. Women without a history of antidepressant use constituted the unexposed cohort.</p><p><strong>Main outcome measures: </strong>We used a multilevel mixed-effects generalized linear model, accounting for multiple embryo transfers, to examine the chance of clinical pregnancy and live birth after ART treatment in women currently or recently treated with antidepressants, compared with women without antidepressants.</p><p><strong>Results: </strong>A total of 1,057 women (median age 35 [interquartile range: 31-39]) were current users and had 2,154 embryo transfers, 1,580 women were recent users and had 2,780 transfers, and 42,861 women without use of antidepressants had 118,212 transfers. The relative risk (RR) of clinical pregnancy in women with current use was 0.97 (95% confidence interval [CI]: 0.90-1.04), and 0.94 (95% CI: 0.79-1.11) for live birth. The confounder-adjusted RR was 0.96 (95% CI: 0.87-1.03) for clinical pregnancy, and 0.96 (95% CI: 0.87-1.00) for live birth among current users. For recent users, the RRs of clinical pregnancy, and live birth were 0.94 (95% CI: 0.87-1.00), and 0.99 (95% CI: 0.85-1.14), respectively, and the adjusted RRs 0.94 (95% CI: 0.86-1.01) for clinical pregnancy and 1.04 (95% CI: 0.90-1.20) for live birth.</p><p><strong>Conclusion: </strong>Based on nationwide data from more than a decade, we found that current or recent use of antidepressants at the time of embryo transfer was not associated with a decreased chance of clinical pregnancy or live birth. The findings suggest that for women treated with antidepressants, ART treatment is as successful as for women without.</p>","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":" ","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147316741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Menstrual tracking technologies and fertility: evaluating accuracy, utility, and impact on time to pregnancy 月经跟踪技术和生育：评估准确性，实用性和对怀孕时间的影响

IF 6.7 1区医学 Q1 OBSTETRICS & GYNECOLOGY

Fertility and sterility

Pub Date : 2026-02-25 DOI: 10.1016/j.fertnstert.2026.02.027

Hannah C. Milad, Sarah C. Cromack, Jessica R. Walter

引用次数: 0

Fertile battle: should all oocytes be frozen, regardless of maturity and reason for cryopreservation? 生育之战：所有的卵母细胞都应该被冷冻，而不考虑成熟度和冷冻保存的原因吗？

IF 6.7 1区医学 Q1 OBSTETRICS & GYNECOLOGY

Fertility and sterility

Pub Date : 2026-02-24 DOI: 10.1016/j.fertnstert.2026.01.028

Daniela Nogueira, Kara N. Goldman, Lan N. Vuong, Dean E. Morbeck, Catherine Racowsky

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Fertility and sterility

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀